Strategy Adherence: A Specific and Rapidly Progressive Deficit in Progressive Supranuclear Palsy

Maksymilian A. Brzezicki, MBBS,1 Marko Bogdanovic, PhD,2 Tim Buchanan, PhD,4 James J. FitzGerald, PhD,1,2,3 and Chrystalina A. Antoniades, PhD1,*

Progressive Supranuclear Palsy (PSP) is a rapidly progressive neurodegenerative tauopathy1 without any disease-modifying treatment. To aid development and evaluation of new treatments, we need a clear understanding of the deficits PSP produces and their progression. PSP patients develop multiple deficits in executive function (cognitive inflexibility, problems with planning, distractibility and impulsivity), apathy, and language problems.2,4 Here we describe a novel cognitive measure, “strategy adherence”, derived from an analysis of how a subject completes the well known cancellation task (Fig. 1). We used OCS-Plus, a tablet-based cognitive testing tool.1 The participant is presented with a screen displaying 30 vegetables (10 cabbages, 10 peppers, 10 carrots) mixed with 30 fruits (10 bananas, 10 pears, 10 apples) and has to select the fruits with a stylus. Plotting the selection order reveals the system used by the participant to work their way through the task. Some proceed in an orderly geographic pattern through the screen of symbols. Others cancel by category (eg, apples then pears etc). Participants following any such strategy throughout the task are deemed “strategy adherent”. Those switching strategy or to a random cancellation part way through the task, or canceling randomly from the outset, are deemed non-adherent.

We studied 27 PSP patients (17 Richardson’s syndrome, 10 PSP-parkinsonism, all in clinically probable or possible diagnostic certainty categories), 51 idiopathic Parkinson’s disease (PD) patients, and 21 healthy controls (HC). Participants were tested five times at three–monthly intervals.

At baseline, only 52% of PSP participants were strategy adherent, versus 96% of PD and 100% of HC participants (P < 0.001 for PSP vs. PD and for PSP vs. HC, chi squared test). The strategy adherence rate for PSP participants decreased rapidly, from 52% at visit 1 to 30%, 22%, 15% and 11% at visits 2 to 5. There was no decrease in strategy adherence in PD or HC groups. Deterioration from baseline in the PSP group was significant at all visits (Related Samples McNemar Test, vs. baseline, V2 P = 0.031, V3 P = 0.008, V4 P = 0.002, V5 P = 0.001). Once an individual lost strategy adherence, they never regained it at any subsequent visit, suggesting irreversible crossing of a significant threshold in cognitive decline. There was no significant difference between PSP phenotypes in strategy adherence at any visit (Fisher’s exact test).

Conventional cognitive measures were insensitive to PSP progression in this short timeframe: Mini Mental State Evaluation (P = 0.86), and Montreal Cognitive Assessment (P = 0.88) (Friedman’s test). The PSP rating scale showed significant change from baseline only at visit 5 (P = 0.04 Friedman’s test; visit 1 vs. visit five pairwise comparison P = 0.039).

The decline in group level performance in PSP is both large and rapid. For trials, if intact SA at baseline were a criterion for entry, a reduction of 58% could be expected in 6 months. This is an extremely strong signal of progression and a potential disease modifying drug could be shown to successfully retard the progression of the cognitive effects of PSP in a short period of time.

Acknowledgments

We thank the participants and their families for their endless support with our research work.

Author Roles

(1) Research project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript: A. Writing of the first draft, B. Review and Critique.

1NeuroMetrology Lab, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom; 2Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom; 3Nuffield Department of Clinical Neurosciences, Clinical Neurology, Level 6, West Wing, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; 4UCB Biopharma S.R.L., Brussels, Belgium

*Correspondence to: Dr. Chrystalina A. Antoniades, Nuffield Department of Clinical Neurosciences, Clinical Neurology, Level 6, West Wing, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; E-mail: chrystalina.antoniades@ndcn.ox.ac.uk

Relevant disclosures and conflicts of interest are listed at the end of this article.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Received 1 April 2021; revised 28 July 2021; accepted 15 August 2021. Published online 4 September 2021 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mdc3.13334
M.A.B.: 1C, 2A, 2B, 2C, 3A, 3B
M.B.: 1C, 3B
T.P.: 3B
J.J.F.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B
C.A.A.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B

**Disclosures**

**Ethical Compliance Statement:** The measurements were obtained during the Oxford study of QUantification In Parkinsonism (OxQUiP), a longitudinal study conducted at the John...
Radcliffe Hospital in Oxford, UK. The study was approved by the research ethics committee and the Health Research Authority (REC 16/SW/0262). The aim of OxQUIP is to develop novel methods of objective disease progression measurement. This is achieved by repeated administration of a battery of tests, according to a structured protocol, at three-monthly intervals. All participants were given written information about the study, and informed consent was obtained prior to participating. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

**Funding Sources and Conflicts of Interest:** The authors have no conflicts of interest. This was study was funded by a grant from UCB Biopharma SRL.

**Financial Disclosures for Previous 12 Months:** JFF was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC).

**References**

1. Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. *Lancet Neurol* 2017;16(7):552–563. https://doi.org/10.1016/S1474-4422(17)30157-6.

2. Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. *Mov Disord* 2017;32(6):853–864. https://doi.org/10.1002/mds.26987.

3. Respondek G, Grimm MJ, Piot I, et al. Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. *Mov Disord* 2020;35(1):171–176. https://doi.org/10.1002/mds.27872.

4. Grimm MJ, Respondek G, Stamelou M, et al. Clinical conditions “suggestive of progressive supranuclear palsy”-diagnostic performance. *Mov Disord* 2020;35(12):2301–2313. https://doi.org/10.1002/mds.28263.

5. Humphreys GW, Dutu MD, Montana L, et al. Cognitive function in low-income and low-literacy settings: validation of the tablet-based Oxford cognitive screen in the health and aging in Africa: a longitudinal study of an INDEPTH Community in South Africa (HAALSI). *J Gerontol B Psychol Sci Soc Sci* 2017;72(1):38–50. https://doi.org/10.1093/geronb/gbw139.